Citigroup Inc Avadel Pharmaceuticals PLC Transaction History

Citigroup Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$12.55 - $17.22 $14,269 - $19,579	1,137 Added 32.25%	4,663 $78,000
Q4 2023 Feb 09, 2024	BUY	$9.64 - $14.59 $8,637 - $13,072	896 Added 34.07%	3,526 $49,000
Q3 2023 Nov 09, 2023	BUY	$10.3 - $15.99 $7,179 - $11,145	697 Added 36.06%	2,630 $27,000
Q2 2023 Aug 10, 2023	BUY	$8.48 - $16.48 $4,808 - $9,344	567 Added 41.51%	1,933 $31,000
Q1 2023 May 11, 2023	BUY	$6.41 - $9.95 $4,083 - $6,338	637 Added 87.38%	1,366 $12,000
Q4 2022 Feb 09, 2023	BUY	$5.02 - $10.0 $351 - $700	70 Added 10.62%	729 $5,000
Q3 2022 Nov 10, 2022	SELL	$2.57 - $7.31 $514 - $1,462	-200 Reduced 23.28%	659 $3,000
Q2 2022 Aug 10, 2022	SELL	$1.07 - $6.95 $393 - $2,557	-368 Reduced 29.99%	859 $2,000
Q1 2022 May 12, 2022	SELL	$5.46 - $8.29 $2,839 - $4,310	-520 Reduced 29.77%	1,227 $8,000
Q4 2021 Feb 10, 2022	SELL	$7.34 - $11.18 $168,930 - $257,307	-23,015 Reduced 92.94%	1,747 $14,000
Q3 2021 Nov 10, 2021	BUY	$6.49 - $9.91 $160,705 - $245,391	24,762 New	24,762 $243,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.